DGAP-News: Neovacs S.A. / Key word(s): Joint Venture Neovacs and Stellar Biotechnologies Announce Launch of Neostell, Joint Venture to Manufacture Kinoids 19.07.2016 / 08:00 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- PRESS RELEASE Neovacs and Stellar Biotechnologies Announce Launch of Neostell, Joint Venture to Manufacture Kinoids Administrative Board and Management Team Appointed Paris (France), Boston, MA (USA) and Port Hueneme, CA (USA), July 19, 2016 - NEOVACS (Alternext Paris: ALNEV) and STELLAR BIOTECHNOLOGIES Inc. (Nasdaq: SBOT) today announced the start of their joint venture company, Neostell SAS, with the holding of its first general assembly. At the meeting, the bylaws for Neostell were approved and the Administrative Board and management team were appointed. The following executives were appointed to the Administrative Board: Bernard Fanget, (Vice President Pharmaceutical Development, Neovacs); Frank Oakes (CEO, Stellar Biotechnologies) and Miguel Sieler (CEO, Neovacs). In addition, the management team will include Bernard Fanget as Chairman of the Board of Directors and President and Olivier Dhellin as CEO. Both also will remain in their current positions at Neovacs. Mr Fanget and Mr Dhellin's experiences in the pharmaceutical industry are essential assets to oversee and ensure the efficient launch of the joint venture production company. Their first mission at Neostell will consist of identifying and reserve trough an option agreement a site for the manufacturing facility. However, major investment in the joint venture will not occur until after the results of the Neovacs ongoing Phase IIb trial with IFNa Kinoid in the treatment of lupus are known. Neostell, with initial capital of 400,000 euros, will be based in the Paris area and set up to manufacture all kinoids developed by Neovacs, starting with IFNα-Kinoid, the company's most advanced product candidate. Neostell also plans to manufacture and sell other KLH-based immunotherapy products for third-party customers worldwide. Bernard Fanget, Chairman and President of Neostell, said: "The Neostell corporation will first focus on the production scale-up of Neovacs' IFNα- Kinoid immunotherapy in anticipation of a Korean market launch, as well as the planned Phase III trial for the treatment of lupus and the Phase IIa study in dermatomyositis. My objectives as president are to make Neostell operational, to effectively access the conjugated vaccines development market and to ultimately make Neostell a profitable business." "This joint venture demonstrates Stellar's commitment to ensuring that immunotherapy developers like Neovacs have both ample capacity of high- quality KLH as well as the infrastructure and expertise to manufacture their KLH-based immunotherapies as they advance to market," said Frank Oakes, President, CEO and Chairman of Stellar Biotechnologies, Inc. "With the Neostell corporation in place and its leadership appointed, we look forward to putting operational teams together to map out the next steps for this growth initiative." About Bernard Fanget, Chairman of Neostell Bernard leads pharmaceutical development activities at Neovacs. He brings more than 30 years of industrial experience in biologics pharmaceutical development. Bernard was Corporate Vice President, Global Industrialization at Sanofi Pasteur. He was previously Senior Vice President, Pharmaceutical Development of Flamel Technologies. About Olivier Dhellin, CEO of Neostell Olivier has 9 years of experience in immunotherapy development and cell- based vaccine manufacturing. He previously held positions at Anosys - a US/ French cell therapy biotech company - and conducted research activities for 7 years at Gustave Roussy Institute (molecular biology and genomics) and Pasteur Institute, where he was a post-doctorate fellow in molecular pharmacology. Prior to that, he spent 4 years as a resident in several hospital departments (pediatrics, pharmacology and biochemistry). Olivier holds a degree in pharmacy (Paris XI University, France) and a PhD in virology (Pierre et Marie Curie University, France). About Stellar Biotechnologies, Inc. Stellar Biotechnologies, Inc. (Nasdaq: SBOT) is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune- stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimer's and inflammatory diseases) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies. About Neovacs Neovacs is a leading biotechnology company that has a proprietary active immunotherapy technology platform (Kinoids) with applications in autoimmune and inflammatory diseases and cancer. The goal of the Kinoid approach is to enable patients to have access to safe, effective, long-lasting treatments for these often life-long diseases. Neovacs is focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy being developed for lupus and dermatomyositis. Neovacs also has several therapeutic vaccines in preclinical development for the treatment of autoimmune diseases, cancer and allergies. www.neovacs.fr Contacts NEOVACS - Corporate Communication & Investor Relations Charlène Masson +33 (0)1 53 10 93 14 cmasson@neovacs.com Investor Relations / Financial Communications Germany - MC Services Raimund Gabriel +49-89-21-02-28-30 raimund.gabriel@mc-services.eu Press / U.S. Inquiries - The Ruth Group Lee Roth / Joseph Green +1-646-536-7012 / 7013 lroth@theruthgroup.com / jgreen@theruthgroup.com --------------------------------------------------------------------------- 19.07.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: Neovacs S.A. 3-5, Impasse Reille 75014 Paris France Phone: +33 (0)1 53 10 93 00 Fax: +33 (0)1 53 10 93 03 E-mail: www.neovacs.fr Internet: info@neovacs.fr ISIN: FR0004032746 WKN: A1CVKR Listed: Regulated Unofficial Market in Stuttgart; Open Market in Frankfurt End of News DGAP News Service --------------------------------------------------------------------------- 483475 19.07.2016
DGAP-News: Neovacs and Stellar Biotechnologies Announce
Top 10 Most Recent News Articles
IAS Marks 42 Years Amid Germany Religious Freedom Win
Bagpipes, country roads and a gathering from six continents made this far more than a routine anniversary reception. The International Association of Scientologists marked its 42nd anniversary at Saint Hill in East Grinstead, England, with thousands of Scientologists and guests arriving as autumn settled over West Sussex. That sort of turnout is a visible statement of...
Continue Reading
Rafay's Third Fast 500 Nod Tracks AI Cloud Buildout
GPU warehouses are easy to admire and brutally hard to operate like a real business. Rafay Systems landing on Deloitte's 2026 Technology Fast 500 for a third straight year is another signal that the AI infrastructure scramble has moved well beyond simply finding chips. Somebody has to turn all that expensive compute into services customers can provision, use, measure and...
Continue Reading
Stanford Forum Puts Industrial AI in the Real World
Factory Data Is Not a Free Lunch A factory dataset is worth precisely nothing if its owner cannot control it. That was the hard-nosed thread running through the ASI City Forum at Stanford on November 17: industrial AI is not just about smarter models or splashy chip announcements. It is about whether manufacturers will trust a system with proprietary operating data,...
Continue Reading
MetaComp's $10M Extension Tests Stablecoin Rails in Trade
A ten-million-dollar check is cheap until the licensing bills start arriving. MetaComp has added roughly US$10 million from Tether and Abu Dhabi-based Further Asset Management, taking its Pre-A and Pre-A+ fundraising to about US$45 million. The important bit is not the headline-sized pile of cash. It is where management says the money is going: licences, compliance...
Continue Reading
Ajman Forum Puts Trust at the Center of Crisis Media
Rumours do not wait politely for a communications team to finish its meeting. That plain reality sat underneath Abdulla bin Mohammed bin Butti Al Hamed's keynote at Ajman Media Forum 2026, and it is a tougher point than the usual talk about reach, engagement, or flashy new technology. In a crisis, an information vacuum gets filled fast, usually by somebody with no...
Continue Reading
RMT’s 12.4% Discount Still Demands a Much Harder Look
A $1.84 gap is staring RMT shareholders right in the face. As of October 31, 2026, Royce Micro-Cap Trust carried a net asset value of $14.82 per share while the market price sat at $12.98. That is roughly a 12.4% discount to NAV, and closed-end fund investors should never wave off a spread like that with a lazy shrug. It may be opportunity. It may also be the market...
Continue Reading
IQSTEL’s 2027 Plan Has Scale but Still Needs Proof
A $313 million nine-month revenue figure gets attention, yet this story is really about whether IQSTEL can finally turn a big telecom pipe into money that sticks. The company grew consolidated revenue 34.5% year over year through September 30, 2026, and third-quarter revenue hit $106.0 million, its second straight quarter above $100 million. That is real operating scale,...
Continue Reading
Qiandaohu Whisky Film Puts Craft Before Market Hype
Three Distillers, One Very Large Question Whisky does not become world-class because a camera crew found a pretty shoreline. That is the blunt truth sitting underneath this Nov. 19, 2026 documentary release from CCTV+. The film follows three international distillers working at three separate whisky distilleries along Qiandaohu, while also lingering on their day-to-day...
Continue Reading
Pennsylvania Rebate Rules Matter Before Year-End Filing
A missed rebate form can sting harder than most people expect, especially when a household has already spent the year watching property taxes, rent, groceries, and every other stubborn bill chew through fixed income. Pennsylvania’s Property Tax/Rent Rebate Program is not glamorous, and it is certainly not an investing story. It is, however, the kind of direct household...
Continue Reading
Vision Marine's Cash Cleanup Meets a Hard Reality Ahead
A boat dealer slashing debt by $27.5 million deserves a nod, even when the rest of the ledger still makes your eyebrows climb. Vision Marine Technologies turned fiscal 2026 into a working-capital cleanup job: inventory came down hard, floor-plan financing nearly vanished, and operating cash flow finally turned positive. For NASDAQ:VMAR, that is real progress. It is not,...
Continue ReadingTop 5 Most Recently Viewed Articles
Global Technology Acquisition Corp. I Initiates Liquidation Process
Global Technology Acquisition Corp. I Announces Dissolution of Operations Global Technology Acquisition Corp. I (Nasdaq: GTAC) finds itself at a pivotal moment, as the company has declared its intent to dissolve and liquidate its operations. This decision arises from the inability to complete an initial business combination within the mandated timeframe outlined in its...
Continue Reading
Empowering Leadership Development: McLean & Company Insights
Leadership Development: Key to Organizational Success In today's fast-evolving work landscape, the significance of leadership development has never been clearer. Global HR research firm McLean & Company emphasizes that cultivating effective leaders at every level is crucial for organizational success. Their comprehensive research highlights a four-step process that...
Continue Reading
Investigation Launched into Aviat Networks, Inc. Securities Fraud
Investigation into Aviat Networks, Inc. Recent developments regarding Aviat Networks, Inc. have raised significant concerns among investors about their financial future. The company is now under scrutiny from legal experts due to possible allegations of securities fraud. The Portnoy Law Firm is actively investigating these issues and has begun reaching out to investors...
Continue Reading
GR Silver Mining Plans $1.76 Million Private Placement Funding
GR Silver Mining Ltd.'s Strategic Private Placement GR Silver Mining Ltd. (GRSL, GRSLF) has announced a plan to raise up to $1.76 million through a non-brokered private placement. This strategic initiative is designed to boost exploration efforts, particularly focusing on expanding resources at the San Marcial Area within the Plomosas Project. Details of the Offering The...
Continue Reading
BRT Apartments Corp. Declares Exciting New Dividend
BRT Apartments Corp. announces a quarterly dividend BRT Apartments Corp. has declared a quarterly dividend of $0.25 per share. Approved by the Board of Directors, this action continues the company’s practice of returning cash to shareholders as part of its ongoing financial plan. It’s a straightforward move that underscores a focus on steady, shareholder-minded...
Continue Reading